Cell & Gene: The Podcast
Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng.
Feb 1, 2024
Jennifer Klarer from The Dedham Group delves into pricing and value for CGTs, addressing misconceptions and solutions. Topics include time to treatment challenges, securing investment, and payer dynamics. Learn about the importance of early commercial planning and navigating evolving payment models for financial stability.
37:17
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Cell and gene therapy requires new pricing strategies addressing access challenges.
- Manufacturers of CGTs must focus on market access planning for successful product launch.
Deep dives
The Evolution of Celen Gene Therapy in Healthcare System
Celen Gene therapy offers a transition from disease management to resolution, posing a notable shift in healthcare. The Dedham Group's support spans from phase one to post-launch, focusing on payer coverage, provider adoption, and patient services. This therapeutic category challenges existing healthcare infrastructures, demanding novel approaches in billing, coding, and streamlining complex ecosystems.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
